BenevolentAI Goes SPAC Route Which Temasek Supports
Posted on 12/07/2021
Founded in 2013, BenevolentAI is a London-based drug discovery firm. BenevolentAI agreed to go public at an implied €1.5 billion valuation via Odyssey Acquisition S.A., an Amsterdam-listed SPAC. Jean Raby, the former CEO of Natixis Investment Management, and Yoël Zaoui, a former Goldman Sachs investment banker are the co-CEOs of the SPAC. BenevolentAI had raised […]
